Global X Genomics & Biotechnology ETF Rating $36.50 -0.67 (-1.81%) As of 03:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock Global X Genomics & Biotechnology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.GNOM Aggregate RatingModerate Buy 2.71Holdings in GNOM have an aggregate rating of Moderate Buy based on 384 analyst ratings issued in the past year covering 23 companies (79.5% of the portfolio).GNOM Aggregate Price Target$36.620.35% UpsideHigh Prediction$36.62Average Prediction$36.62Low Prediction$36.62Holdings in GNOM have an aggregate price target of $36.62 and a range of $36.62 to $36.62 covering 23 companies (79.5% of the portfolio).GNOM Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Global X Genomics & Biotechnology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 GNOM Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.79%ALNYAlnylam Pharmaceuticals$469.00+0.1%3.7963 of 5 stars2.85$421.28 -10.2%27Positive NewsAnalyst ForecastInsider Trade5.75%RNAAvidity Biosciences$45.60+11.1%2.1142 of 5 stars3.06$68.33 49.8%18Trending NewsAnalyst ForecastInsider TradeGap UpHigh Trading Volume5.13%GHGuardant Health$54.39-4.2%4.1117 of 5 stars3.06$58.24 7.1%18News CoveragePositive NewsInsider TradeGap Down5.00%CRSPCRISPR Therapeutics$55.94+0.1%3.3026 of 5 stars2.47$71.60 28.0%17Positive News4.72%ILMNIllumina$95.50-3.8%4.8453 of 5 stars2.21$123.06 28.9%19Positive News4.10%NTRANatera$169.57-2.4%3.6719 of 5 stars3.06$194.00 14.4%18Positive News3.96%QGENQiagen$45.43-1.4%4.453 of 5 stars2.27$49.69 9.4%11Positive News3.93%TECHBio-Techne$51.37-3.5%4.9889 of 5 stars2.77$70.42 37.1%13Positive News3.82%WGSGeneDx$124.66-1.0%2.5861 of 5 stars2.75$104.13 -16.5%8Positive NewsAnalyst Forecast3.64%LEGNLegend Biotech$33.08-2.2%3.2748 of 5 stars2.91$74.22 124.3%11Positive News3.38%BMRNBioMarin Pharmaceutical$54.19-3.1%4.947 of 5 stars2.69$92.04 69.9%26Short Interest ↑3.35%MRNAModerna$23.54-7.3%4.5036 of 5 stars2.04$42.88 82.2%24Positive NewsHigh Trading Volume3.22%BNTXBioNTech$96.35-7.6%2.5209 of 5 stars2.76$135.80 40.9%17Positive NewsHigh Trading Volume3.03%ARWRArrowhead Pharmaceuticals$30.12+1.3%4.1472 of 5 stars3.00$43.14 43.2%8Analyst Revision2.95%RAREUltragenyx Pharmaceutical$30.47-2.4%4.4799 of 5 stars2.92$81.50 167.5%12Positive NewsAnalyst Forecast2.89%VRTXVertex Pharmaceuticals$393.94-0.9%4.9108 of 5 stars2.57$496.05 25.9%28News CoveragePositive NewsAnalyst Forecast2.74%VCYTVeracyte$30.97-2.8%3.8619 of 5 stars2.70$40.90 32.1%10Positive News2.16%AAgilent Technologies$123.34-2.7%4.6746 of 5 stars2.50$139.25 12.9%12Positive News1.92%GILDGilead Sciences$115.69-1.8%4.9052 of 5 stars2.89$115.39 -0.3%27Positive News1.78%TWSTTwist Bioscience$25.06-2.2%3.987 of 5 stars2.73$49.40 97.1%11News Coverage1.75%BMYBristol Myers Squibb$46.26-2.7%4.8683 of 5 stars2.24$56.38 21.9%21Positive News1.73%TXG10x Genomics$12.63-3.3%3.6536 of 5 stars2.33$13.65 8.1%15News CoverageAnalyst Forecast1.72%BEAMBeam Therapeutics$20.54-4.7%2.861 of 5 stars3.08$46.40 125.9%13 This page (NASDAQ:GNOM) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
